News | October 15, 2014

RSNA Receives NIBIB Funding for QIBA Research

RSNA has received an additional $1.27 million of funding from the National Institute of Biomedical Imaging and Bioengineering to support research by the Quantitative Imaging Biomarkers Alliance

October 15, 2014 – The Radiological Society of North America (RSNA) has received an additional $1.27 million of funding from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) to support research by the Quantitative Imaging Biomarkers Alliance (QIBA). This marks the fourth consecutive year that NIBIB has funded research groundwork by QIBA, following a 2013 contract for $1.25 million.

Quantitative imaging is the extraction of quantifiable features from medical images for the assessment of normal or the severity, degree of change or status of a disease, injury or chronic condition relative to normal.

Quantitative imaging includes the development, standardization and optimization of anatomical, functional and molecular imaging acquisition protocols, data analyses, display methods and reporting structures. These features permit the validation of accurately and precisely obtained image-derived metrics with anatomically and physiologically relevant parameters, including treatment response and outcome, and the use of such metrics in research and patient care.

QIBA is an initiative organized by RSNA in 2007 to advance quantitative imaging and the use of imaging biomarkers in clinical trials and practice.

QIBA engages researchers, healthcare professionals and industry stakeholders by collaborating to identify needs, barriers and solutions to develop and test consistent, reliable, valid and achievable quantitative imaging results across imaging platforms, clinical sites and time. QIBA also works to accelerate the development and adoption of hardware and software standards needed to achieve accurate and reproducible quantitative results from imaging methods.

A portion of the new NIBIB award has been earmarked to support QIBA projects and activities, including development of a Quantitative Imaging Data Warehouse, research to characterize the sources of bias and achievable precision associated with quantitative imaging, and to further develop and test phantoms and digital reference objects.

 

“We are honored and gratified that NIBIB continues to recognize the importance of objective, quantitative results from imaging studies to patient care, and provides ongoing support for QIBA’s foundational work in this effort,” said Daniel C. Sullivan, M.D., QIBA Chair.

 

For more information visit: www.rsna.org

Related Content

Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pitt
The FDA issued new warnings on MRI gadolinium contrast agents. (GBCAs)

The FDA issued new warnings on MRI gadolinium contrast agents. 

Feature | Magnetic Resonance Imaging (MRI) | December 19, 2017
The U.S.
Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance
Technology | Contrast Media | December 12, 2017
Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology,...
Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring s
Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Overlay Init